GuidelineClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.
Guideline in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 308 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
308 citing papers in PubMed, 6 syntheses or guidelines pooled it, 748 citations in OpenAlex.
- MT-RNR1 genotype testing for preventing aminoglycoside-mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).British journal of clinical pharmacology · 2026Guideline
- The European respiratory society guideline for adult bronchiectasis 2025: summary and implementation guide for primary care.NPJ primary care respiratory medicine · 2026Guideline
- Non-tuberculous mycobacterial infections among pulmonary tuberculosis suspected and confirmed patients in Ethiopia - A systematic review and meta analyses.BMC infectious diseases · 2025Pooled it
- Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.Frontiers in microbiology · 2025Pooled it
- Global trends in the proportion of macrolide-resistant Mycobacterium Species: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Prevalence ofFrontiers in microbiology · 2024Pooled it
- Trial
- Macrolide-resistantJournal of clinical tuberculosis and other mycobacterial diseases · 2026Review
- Clinical impact of chronic pulmonary aspergillosis in patients with pulmonary nontuberculous mycobacterial disease and colonization: a multicentre prospective cohort study.Annals of medicine · 2026Article
- Blood transcriptomic signatures distinguishEmerging microbes & infections · 2026Article
- Clinical performance of the Abbott RealTime Mycobacterium tuberculosis (MTB) PCR on bronchoscopic specimens for diagnosing pulmonary tuberculosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Fatal Persistent Cavitary Mycobacterium avium Complex Pulmonary Disease in a Non-HIV Patient With Prior Malignancy.Cureus · 2026Article
- Article
- Prevalence and Genotypes of Mycobacteria Species in Formalin-Fixed Paraffin-Embedded Tissue Samples in a Tertiary Laboratory, Northern Pretoria, South Africa.Diagnostics (Basel, Switzerland) · 2026Article
- Differential activation of NF-Κβ and HIF-1α between fetal liver-derived and myeloid-derived macrophages drives inflammatory differences followingInfection and immunity · 2026Article
- Documenting Environmentally Acquired Mycobacterium intracellulare subsp. chimaera Pulmonary Disease Soon After Bronchiectasis Onset.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Th2 bias and T-cell exhaustion characterize the immunopathology of non-tuberculous mycobacterial pulmonary disease.NPJ systems biology and applications · 2026Article
- A Rare Manifestation of Mycobacterium kansasii as a Cutaneous Infection: A Case Report.Cureus · 2026Article
- Leveraging rpoB amplicon signals from Xpert MTB/RIF ultra as a diagnostic opportunity for identifying Non-tuberculous mycobacteria in TB-negative specimens.Scientific reports · 2026Article
- The peptidoglycan-binding domain regulates antimycobacterial activity of LysB by affecting its transportation and/or catalytic activity.Communications biology · 2026Article
248 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 16 institutions in 9 countries.
Funding
Abstract
Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.